Calidi Biotherapeutics Inc.
CLDI | AMEX
$1.13
+$0.02 (+1.59%)
Sep 22, 2026, 12:21 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | 45K | 449K | n/a |
Cost of Revenue | 1.65M | n/a | 1.26M | 274K | 94K | n/a |
Gross Profit | -1.65M | n/a | -1.26M | -229K | 355K | n/a |
Operating Income | -20.24M | -21.78M | -28.99M | -23.13M | -10.48M | -6.77M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -20.05M | -22.2M | -29.2M | -25.42M | 3.4M | -7.93M |
Net Income | -19.91M | -22.14M | -29.22M | -25.43M | -10.93M | -7.94M |
Selling & General & Admin | 10.5M | 12.9M | 15.98M | 15.64M | 6.16M | 3.59M |
Research & Development | 9.74M | 8.88M | 13.01M | 7.26M | 4.67M | 3.18M |
Other Expenses | -1.65M | n/a | -1.26M | n/a | n/a | n/a |
Operating Expenses | 18.59M | 21.78M | 27.74M | 22.9M | 10.84M | 6.77M |
Interest Expense | 207K | 933K | 3.75M | 158K | 614K | 163K |
Selling & Marketing Expenses | n/a | n/a | n/a | -260K | n/a | n/a |
Cost & Expenses | 20.24M | 21.78M | 28.99M | 23.17M | 10.93M | 6.77M |
Income Tax Expense | 15K | 14K | 16K | 11K | 11K | 4K |
Shares Outstanding (Basic) | 268.88K | 41.53K | 8.76K | 4.41K | 14.91K | 186.27K |
Shares Outstanding (Diluted) | 268.88K | 41.53K | 8.76K | 4.41K | 14.91K | 186.27K |
EPS (Basic) | -95.20 | -571.20 | -3.32K | -5.74K | 226.56 | -42.24 |
EPS (Diluted) | -95.20 | -571.20 | -3.32K | -5.74K | 226.56 | -42.24 |
EBITDA | -18.19M | -19.73M | -24.2M | -25M | -9.45M | -6.67M |
EBIT | -19.84M | -21.26M | -25.45M | -25.26M | -9.61M | -6.77M |
Depreciation & Amortization | 1.65M | 1.54M | 1.26M | 260K | 156K | 107K |
Add to Watchlist
Select watchlists to add or remove CLDI